PLATINUM China: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of a Single De Novo Coronary Artery Lesion

Trial Profile

PLATINUM China: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of a Single De Novo Coronary Artery Lesion

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2015

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PLATINUM-China
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 27 Jan 2011 New trial record
    • 26 Jan 2011 First patient enrolled, according to a Boston Scientific Corporation media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top